Stay updated with breaking news from Mark Rothera. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
04.01.2024 - Speed to market strategy for Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supported by complete enrollment of Stage 1, complete enrollment of Stage 2 anticipated in Q1 2024 and engagement with the FDA on potential ... Seite 1
SAN DIEGO, Aug. 07, 2023 -- Viracta Therapeutics, Inc. , a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...
Viracta Therapeutics Inc (NASDAQ: VIRX) announced that the relapsed or refractory EBV+ peripheral T-cell lymphoma (R/R EBV+ PTCL) cohort of their pivotal NAVAL-1 clinical trial met the pre-specified efficacy threshold for
SAN DIEGO, Jan. 19, 2023 -- Viracta Therapeutics, Inc. , a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today... | January 19, 2023
Partial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV+ recurrent/metastatic (R/M) nasopharyngeal...